Response to: Biosimilars for vasculitis: promise requires validation by quality studies

Clin Rheumatol. 2020 Oct;39(10):3155-3156. doi: 10.1007/s10067-020-05381-0. Epub 2020 Sep 2.

Authors

Sakshi Mittal¹, G S R S N K Naidu¹, Aman Sharma²

Affiliations

¹ Department of Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
² Department of Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India. [email protected].

PMID: 32876783
DOI: 10.1007/s10067-020-05381-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Biosimilar Pharmaceuticals*
Drug Approval
Drug Industry
Humans
Qualitative Research
Vasculitis*

Substances

Biosimilar Pharmaceuticals